BSX (Boston Scientific) 3-Month Share Buyback Ratio: 2.66% (As of Jun. 2026 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSX Boston Scientific Corp BSX
77 GF Score
Price $50.37
GF Value $106.96
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Boston Scientific 3-Month Share Buyback Ratio?

Boston Scientific BSX +2.03% 77 3-Month Share Buyback Ratio is 2.66 as of Jun. 2026. GuruFocus rates BSX with a GF Score™ of 77/100 and a GF Value™ of $106.96 (Significantly Undervalued). The stock has 1 warning sign investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Boston Scientific's current 3-Month Share Buyback Ratio was 2.66%.


Boston Scientific  (NYSE:BSX) 3-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


Boston Scientific 3-Month Share Buyback Ratio Related Terms


BSX vs EW, DXCM, GEHC: 3-Month Share Buyback Ratio Comparison

For the Medical Devices subindustry, Boston Scientific's 3-Month Share Buyback Ratio, along with its competitors' market caps and 3-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Boston Scientific 3-Month Share Buyback Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's 3-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Boston Scientific's 3-Month Share Buyback Ratio falls into.


BSX
77GF Score
Boston Scientific Corp BSX
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Boston Scientific 3-Month Share Buyback Ratio Calculation

Boston Scientific's 3-Month Share Buyback Ratio for the quarter that ended in Jun. 2026 is calculated as

3-Month Share Buyback Ratio=(Shares Outstanding (EOP) (Mar. 2026 ) - Shares Outstanding (EOP) (Jun. 2026 )) / Shares Outstanding (EOP) (Mar. 2026 )
=(1486.294 - 1446.706) / 1486.294
=2.66%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 3-Month Share Buyback Ratio of 2.66 mean?
Boston Scientific (BSX) has a 3-Month Share Buyback Ratio of 2.66 as of Jun. 2026. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Boston Scientific and its competitors.
Is Boston Scientific's 3-Month Share Buyback Ratio too high?
Boston Scientific's current 3-Month Share Buyback Ratio is 2.66. Overall, Boston Scientific has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Boston Scientific's 3-Month Share Buyback Ratio compare to EW and DXCM?
Boston Scientific's 3-Month Share Buyback Ratio of 2.66 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Medical Devices & Instruments company?
A good 3-Month Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Boston Scientific and its competitors. Boston Scientific's current 3-Month Share Buyback Ratio is 2.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boston Scientific stock overvalued right now?
Based on GuruFocus' analysis, Boston Scientific (BSX) is currently considered Significantly Undervalued. The stock's GF Value™ is $106.96, compared to a current price of $50.37 — trading 52.9% below its estimated fair value. The current 3-Month Share Buyback Ratio is 2.66. Boston Scientific's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Boston Scientific (BSX), the current 3-Month Share Buyback Ratio is 2.66 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Boston Scientific (BSX) Overvalued in 2026?

Based on GuruFocus' analysis, Boston Scientific stock appears to be undervalued. The current stock price of $50.37 is trading 52.9% below its estimated GF Value™ of $106.96. GuruFocus considers Boston Scientific to be Significantly Undervalued.

Key valuation signals for BSX:

  • 3-Month Share Buyback Ratio: 2.66
  • GF Value™: $106.96 vs. price of $50.37 (52.9% below fair value)
  • GF Score™: 77/100 with 1 warning sign

No single metric tells the full story. See the BSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Boston Scientific Business Description

Address 300 Boston Scientific Way, Marlborough, MA, USA, 01752-1234
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
77GF Score

Get the complete analysis for BSX

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$50.37
Price
$106.96
GF Value